Poly Medicure Ltd

- For FY 2024-25, Poly Medicure Limited expects revenue growth of around 20%+, with a possibility of upward revision after Q1 or early Q2 based on actual performance. - Domestic business aims to improve growth from 18.5% to about 22%-23% next year, driven by deeper market penetration and new divisions scaling up. - Renal segment is expected to grow over 50% next year, rising from INR 90 crores to INR 140-145 crores, aided by regulatory traction and capacity expansion. - Export business, especially Europe (40%+ of export revenue), continues to show strong growth (~35%-40%). - EBITDA margin for the 9 months stands near 26%, in line with guidance; operational leverage from new plants is expected to improve margins over coming years. - PAT has grown significantly (57% increase in 9 months) and is expected to maintain healthy growth consistent with revenue and margin expansion.

- Poly Medicure Limited has contracts in place for the U.S. business and has started selling products there. - The expected buildup in U.S. revenue is $15 million to $20 million annually by FY-28. - The company is already sending initial shipments and receiving clinical feedback from U.S. customers. - The company maintains a safety stock of raw materials covering 2 months to mitigate supply chain disruptions (e.g., Red Sea crisis). - No specific current orderbook or pending order values were disclosed in exact terms during the call. - The focus remains on scaling up shipments, product approvals, and expanding market share across regions, including domestic and export markets.

- There is no explicit mention of plans for new fundraising through debt or equity in the provided transcript. - The company is currently in a high capex cycle, having spent around INR 185 crores in the first 9 months, with plans to spend up to INR 230-240 crores this financial year and INR 100-150 crores next year. - The company has a high cash balance on its balance sheet (over INR 150 crores) and strong operating cash flows. - The focus appears to be on utilizing internal accruals for ongoing capex and growth rather than raising new funds externally. - The company is also looking at potential inorganic opportunities in the future, but no specific mention of equity or debt fundraising linked to those was made.

- In the first 9 months, Poly Medicure has spent around INR 185 crores on capex and expects to exceed this with a total of INR 230-240 crores for the full year. - Four new plants: 2 already operational in Faridabad, 1 in Jaipur SEZ, and 1 under final stages of construction to be ready by early next financial year (April-May). - Next year, additional capex of INR 100-150 crores planned to add more equipment and machines. - New plants currently operating at 30-40% utilization; full ramp-up expected by end of the year. - Capex focused on expanding manufacturing capacity for existing and new divisions such as renal, critical care, and cardiology. - Plans for setting up own gamma sterilization facility to reduce dependence on external vendors. - Looking at possible inorganic opportunities after current capex cycle tapers down.

- The company targets a 20% growth in revenue for the next year, starting with a moderate estimate to revise upward after Q1 or early Q2. - Domestic business is expected to grow around 22%-23%, driven by deeper market penetration and expansion of new divisions including renal, cardiology, and critical care. - Renal segment projected to scale up sharply with an anticipated 50% growth next year, compared to 22% growth this year. - Export business, especially Europe which accounts for ~40% of export revenues, is showing strong growth (40%+). - US market entry underway with expected revenue buildup to $15-20 million annually by FY28. - Overall, exports have grown by ~23.5% in nine months, domestic by ~18.5%. - Increasing salesforce in India by ~100 people per year to boost productivity and coverage (5,000+ hospitals covered currently). - New manufacturing plants and capacity expansions aim for full utilization by year-end, supporting scaling volumes and revenue growth.